Effective Financial Management of Clinical Trials: Issues and Challenges

Victor Lampasona, PharmD Assistant Vice President for Research Office of Research Administration Emory University Atlanta, GA

Background

- Clinical trial market is a competitive business
- Clinical trial budgets follow a business model vs. Federal-funding model
- Clinical trial hidden costs can be significant
- Typical payment schedules sluggish leaving sites to carry cost for months

Outline

- Discuss clinical trial (CT) budgeting process
 - Define approach to define a comprehensive budget
- List issues and challenges in the CT budgeting process
- Discuss strategies to improve CT budgeting effectiveness

- Common fixed costs: laboratory, x-ray, EKG, etc.
- Related costs: phlebotomy fees, supplies, specimen processing fees
- Drug costs: investigational drug management/dispensing, alternative or adjunct drugs
- Subject costs: travel, parking, time compensation
- Ancillary costs: travel, pager/phone, administrative (copying, long distance phone)
- Marketing costs: radio, newspaper ads, etc.

- Study Personnel: research nurse/coordinator, investigator
 - budget by time estimate or milestone (per visit,etc)
 - use actual salary values
- Institutional Fees:
 - IRB
 - Contracting
 - Overhead or indirect costs
- Record Retention Fees

- "Hidden" costs:
 - Time/cost to obtain special reports (UB 92)
 - Copy cost for X-rays, MRIs etc.
 - Cost increases for studies that go on later than one year
 - inflation, health system price increases, etc.
 - Personnel costs
 - screening, training of staff, failed enrollment, etc
 - Cost of starting enrollment late

- "Hidden" costs:
 - Sponsor imposed costs -
 - monitoring visits
 - poorly trained monitors
 - monitor turn-over during course of study
 - inefficient handling of study queries and data corrections
 - processing amendments

Evaluating the Trial Opportunity

- Business Analysis:
 - Financially sound study?
 - Cost of doing trial < Budget payments
- Academic Analysis:
 - Quality of the Science?
 - Phase I, II > Phase III, IV
- Right Answer: balance between the two

Evaluating the Trial Opportunity

- Evaluate long term financial risk of the study
 - financially "positive" at first, financially "risky" later
- Participate in financially "risky" trial?
 - Interest in disease state or investigational agent
 - Investigator/Department decision
 - Novel therapeutic intervention
 - only accessible in clinical trial
 - Differentiate AMC within the community

Clinical Trial Budgeting Issues

- Define study costs vs. standard of care
 - a priori determination works best
 - who does this?
 - Investigator, IRB, other committee?
 - specify major study costs in consent form
 - if grant will not support, notify subject they are responsible
 - billing process document study payments
 - audit trail

Clinical Trial Budgeting Issues

- Clinical trial budgets are usually fixed
 - usually broken into "per subject" payments
 - payments prorated based on subject completion
 - must "back into" sponsors bottom line
 - overhead/indirect costs may be included in fixed budget
- Study costs increase over the time the study is underway
 - study could become financially "risky"

- Accounting for subject screening costs
 - May be unpredictable
 - many times not listed in budget
 - Screening failures
 - reimburse as a ratio of enrolled subjects
 - reimburse only a fixed number
 - usually reimbursed at end of trial
- Understand payments for "partial" or "nonevaluable" subjects

- Recovering cost for sponsor decisions
 - placing studies "on-hold"
 - closing studies early
- Payment milestones based on monitor visits – dependent on monitor's schedule and efficiency
- Differentiate study payments vs. normal charge/payments in billing system
 - list research as another "payor"

- Incentive payments
 - many times not included in study contract
 - how to handle appropriately?
 - Include in study contract
 - Conflict of interest issues
 - IRB concerns
 - Go directly to investigator?
 - Place in educational fund?
 - Institutional policy

- Study account residual dollars
 - Who controls disposition of left over \$s?
 - May be motivation for investigator to participate in trial
 - Incentive for investigator not to "cost account" study?
 - Tax consequences for non-profit AMCs?

- Budget development process
- Negotiating the budget
- During the course of conducting the study

- Budget Development Process
 - Understand costs at your site
 - Use standardized cost templates
 - Define "research costs" for procedures, etc.
 - Choose "good" studies
 - Financial outcome based on objective assessment

- Budget Development Process
 - Know your "break even" point
 - How long can you go without enrolling your 1st subject?
 - Plan to make periodic financial evaluations
 - Get insight from experienced clinical research staff
 - Expertise of the person creating the budget
 - need clinical and financial perspective

- Negotiating the Budget
 - Fixed per subject payment?
 - May still be negotiable
 - Overhead or indirect cost included?
 - Understand "one-time" costs
 - IRB fee, etc
 - Establish flexibility to cover "pass through" costs
 - Prn procedures (f/u CT scans, MRI, etc)

- Negotiating the Budget
 - Negotiation tools:
 - Past performance by investigator or site
 - Data base of potential subjects

- Negotiating the Contract
 - Initiation or start-up payment
 - Negotiate as "non-refundable" to cover screening/enrollment costs
 - Evaluate payment schedule/milestones based on your cost

- During the Conduct of the Study
 - Know where your costs are
 - Keep track of screening/enrollment costs
 - Use research "CPT codes" for study procedures
 - Evaluate "break even" point
 - Define criteria to end study at your site
 - Make a business decision

Clinical Trial Budgeting Additional Strategies

- Timing the start of the study
 - Efficient start-up process
- Knowing when it is time to quit
 - Screening/enrollment costs >> reimbursement
- Utilize electronic budgeting software
 - SiteWorks Solutions
 - Study Manager

Clinical Trial Budgeting Additional Strategies

- Negotiate your own incentives
 - Based on performance
 - rapid start-up time
 - rapid subject enrollment
- Select the best balance of studies
 - Target enrollment 3subjects, 30 subjects

Effective Financial Management of Clinical Trials Summary

- Identify all study-related costs *a priori*
- Address the issues specific to your site
- Experienced CT budgeting staff may be best strategy
 - however, maintain a relationship with investigator
- Continue to assess CT finances during the conduct of study